TLRY — —
Loading…
— —
PREV CLOSE — OPEN — DAY RANGE —
Analyzing 0%
MASTER — —
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN Ranks Forecast News Intelligence Fundamentals ESEN Deep Analysis Screener
I'll provide you with a comprehensive institutional analysis of TLRY based on the live data provided. Let me first search for current Wall Street analyst price targets. Now I'll produce the institutional research report:
ESEN MASTER SCORE SUMMARY
Metric Grade Score Evidence Horizon
FINAL ESEN MASTER SCORE D+ 41 Composite of all below metrics; sustained negative EPS, collapsing valuation, extreme volatility 6-12M
Growth Sustainability & Moat C- 48 Revenue growth only 3.82% YoY; hyper-growth flagged but offset by -1.95 EPS; weak structural moat in commoditized cannabis 6-12M
Valuation & Safety (Pre-Penalty) D 38 No meaningful P/E (negative EPS); price at 52-week low ($3.67); 52W drawdown -30.85%; market cap $469M on slowing growth 1-3M
Institutional & Smart Money Flow D 35 Analyst consensus scattered (median $2.00–$9.25 across sources); recent downgrades reflect cautious outlook; limited institutional support visible 1-3M
Volatility & Drawdown Risk D- 32 Beta 1.95 (elevated); 52W range $3.67–$23.20 (532% span); -30.85% YTD return; 0.04 intraday swing (-0.99%) shows continued instability 1-3M
Confidence Score C 52 Data coverage: earnings date and recent fundamentals partially constrained; analyst dispersion high; structural cannabis headwinds well-documented 6-12M
Penalty Overlay F 0 Negative profitability (EPS -1.95), weak balance sheet flagged, no dividend; penalizes by ~15–20 points 6-12M
OPERATIONAL & MARKET SNAPSHOT
Price (USD)
$3.99
Market Cap
$469M
EPS
-$1.95
Revenue Growth (YoY)
+3.82%
Beta
1.95
52W High / Low
$23.20 / $3.67
52W Return
-30.85%
Avg Vol (M)
4.72M
PEER & SECTOR CONTEXT

Tilray occupies the cannabis therapeutics / pharmaceutical crossover segment, a crowded and structurally challenged space. The "Pharmaceuticals" sector label masks underlying cannabis commodity dynamics: oversupply in Canada, regulatory fragmentation in the US, and persistent margin pressure. Comparable pure-play cannabis peers (Cronos, Canopy Growth) face similar headwinds. Tilray's 3.82% revenue growth trails inflation and most pharma subsectors, while operating at a loss. Its beta of 1.95 reflects both sector volatility and company-specific execution risk. The 52-week range of $3.67–$23.20 (532% span) underscores investor sentiment whipsaw and weak fundamental anchors.

DUAL-HORIZON ANALYTICAL VIEW
Horizon Assessment Key Driver
1–3 Months Cautionary; elevated downside risk. Price at 52W low signals capitulation, but technical support weak. Negative EPS and cash burn dynamics argue for defensive stance. Any near-term catalyst (M&A, US regulatory shift) could swing sentiment sharply, but not factored into base case. Momentum exhaustion; technical support breakdown; earnings visibility poor
6–12 Months Structural headwinds persist. Revenue growth must accelerate meaningfully (to 8–10% minimum) to justify a recovery valuation. Profitability inflection currently absent from guidance. Macro cannabis sentiment remains weak, but US legalization upside is optionality. Long-term bull thesis requires transformational M&A or market-share gain; base case does not warrant accumulation yet. Profitability path unclear; Cannabis policy tailwinds uncertain; M&A potential (binary)
CONVICTION VERDICT
HOLD / AVOID — Tilray shows acute structural and cyclical challenges: negative earnings, minimal growth, extreme volatility, and weak analyst conviction. Current price ($3.99) reflects distress; no safety margin evident for long-only investors. Upside optionality exists (US cannabis catalysts, M&A), but requires risk tolerance and a 12+ month horizon. Not suitable for conservative or income-oriented mandates.
ANALYST PRICE TARGET CONTEXT

Wall Street Consensus (Current): Consensus price target of US$11.69 , though analysts have adjusted their fair value estimate from $8.50 to $9.25 . Recent data suggests 2 Wall Street analysts issued a 1-year TLRY price target with an average of $8.50, with a high of $10.00 and a low of $7.00 . This implies 113–188% upside from current levels, but analyst dispersion is elevated and recent commentary has grown increasingly cautious around revenue visibility and margin sustainability.

Note: Target ranges vary materially across sources ($7.25–$11.69). Some outlier models (e.g., StockScan, technical proxies) project 2026 fair value of $19.91 or higher, but these are not consensus Street views and carry significant uncertainty. Use consensus ($9.25–$11.69) with caution given recent downgrades and profit visibility constraints.

ESEN News Intelligence — TLRY
Tilray Brands Inc | Institutional Summary
Sentiment: Mixed Impact: Medium
Executive Summary
Tilray reported raised FY2026 guidance driven by $10M annual cost savings from Canadian operations consolidation. The company is executing structural optimization—closing four beverage facilities and reducing SKUs to adapt to industry shifts. Recent news highlights strategic non-participation in Aurora Cannabis acquisition activity. Cannabis rescheduling developments and competitive position analysis remain material to medium-term outlook. Stock up 1.28% (Nov 17), though 52-week return remains significantly negative at -78.50%.
Recent Material News (Last 14 Days)
Tilray Raises Guidance Amid Cost Optimization
November 7, 2026
Company announced raised FY2026 guidance with ~$10M in annual cost savings from consolidating Canadian operations, signaling operational efficiency improvements across cannabis segment.
Brewery Portfolio Restructuring and Facility Closures
November 10, 2026
Tilray closed four beverage facilities and reduced SKU count targeting $20M cost savings, reflecting adaptation to shifting consumer demand and competitive pressures in craft beverage market. Shock Top brand included in portfolio review.
Strategic Positioning: Aurora Cannabis Acquisition Interest
November 10, 2026
News analysis noted Tilray has not pursued acquisition interest in Aurora Cannabis despite multiple third-party bids. Strategic implications for competitive consolidation in Canadian cannabis sector remain under review.
Cannabis Rescheduling Impact Assessment
November 7, 2026
Media coverage evaluated potential regulatory benefits from U.S. cannabis rescheduling (Schedule I to Schedule III), with mixed views on direct translation to Tilray's near-term valuation and market positioning.
Key Metrics Snapshot
Metric Value
Current Price $2.37
52-Week High / Low $15.70 / $2.41
52-Week Return -78.50%
Revenue Growth YoY +15.93%
EPS (TTM) -$1.39
Beta 2.18
Compliance Note: This summary reflects material public news from November 2026 based on available institutional data. No investment recommendation is implied. Investors should consult current financial filings, forward guidance updates, and regulatory developments. Tilray exhibits elevated volatility (beta 2.18) and negative profitability; cost restructuring remains under execution. Data current as of November 17, 2026, 18:49 UTC.
SNAPSHOT
Ticker
TLRY
Company
Tilray Brands
Sector
Pharma
Market Cap
$644M
Price
$4.70
Change
+0.43%
52W High
$23.20
52W Low
$3.67
52W Return
-62.4%
Beta
1.92
EARNINGS MOMENTUM

Data Constraint: Earnings history (last 4 quarters EPS actuals, estimates, surprises) and forward EPS guidance are not disclosed in current dataset. Coverage is limited to TTM metrics.

Metric Value Assessment
EPS (TTM) -$1.06 Negative
EPS Growth YoY No Data Earnings remain deeply unprofitable
Revenue Growth YoY +11.46% Positive Growth
Forward P/E Not Available Cannot estimate forward earnings
Earnings Date Not Disclosed Next earnings not scheduled in dataset

Key Insight: TLRY shows modest top-line revenue growth (+11.46% YoY) but remains deeply loss-making with negative EPS of -$1.06. The company is classified as hyper-growth but has not achieved profitability. Without forward guidance or recent quarterly surprise patterns, earnings momentum cannot be fully assessed.

⚠ Earnings Momentum Score: 4/10 | Direction: Stalled — Negative EPS with weak forward visibility
PROFITABILITY & QUALITY

Data Constraint: Detailed margin data (gross, operating, net), ROE, ROIC, and free cash flow are not available in current coverage.

Metric Value Signal
Net Margin Limited Visibility EPS negative indicates significant margin compression
Gross Margin Not Disclosed Pharmaceutical sector typically 60-80%
Operating Margin Not Disclosed Loss-making company implies negative op margin
ROE / ROIC Not Available Likely negative given EPS profile
Free Cash Flow TTM Not Disclosed Cash burn likely given negative earnings
Quality Flag Strong Profitability: NO System flag confirms unprofitable status

Key Insight: TLRY exhibits poor profitability metrics across the board. Negative EPS and the absence of disclosed margins, ROE, or FCF indicate the company is in a cash-burn phase. System flags explicitly mark "strong_profitability: false."

✗ Quality Score: 2/10 | Profitability Verdict: Critical — Loss-making with no margin visibility
BALANCE SHEET HEALTH

Data Constraint: Cash position, total debt, net debt, EBITDA, interest coverage, and current ratio are not disclosed in current dataset.

Metric Value Risk Assessment
Cash Position Not Available Unable to assess liquidity runway
Total Debt Not Available Unable to assess leverage
Net Debt / EBITDA Not Available Cannot calculate
Current Ratio Not Available No visibility on short-term liquidity
Interest Coverage Not Available Negative EBIT makes this irrelevant
Share Dilution No Data Loss-making biotech typically faces dilution risk
System Flag Weak Balance: NO System does not flag balance sheet as weak, but data gaps are material

Key Insight: Despite system flags not explicitly marking balance sheet weakness, the complete absence of cash, debt, and liquidity metrics prevents full assessment. A loss-making company with $644M market cap carries implicit liquidity risk and likely faces ongoing capital needs.

⚠ Balance Sheet Risk: MEDIUM-HIGH | Verdict — Data gaps prevent full assessment; implicit refinancing risk given losses
VALUATION ANALYSIS
Metric Value Assessment
P/E Ratio (Trailing) Not Applicable Company is unprofitable (EPS = -$1.06)
Forward P/E Not Available No consensus forward earnings
PEG Ratio Not Calculable Requires forward EPS growth; loss-making baseline
P/S Ratio ~5.6x Elevated for a loss-making biotech
EV / EBITDA Not Available Likely negative or undefined (loss-making company)
P/FCF Not Available No FCF disclosed; cash burn likely
System Valuation Flag High Valuation: NO System does not flag overvaluation, but metrics are distorted

Key Insight: Traditional valuation metrics (P/E, forward P/E, PEG) are inapplicable for a loss-making company. The P/S of ~5.6x is elevated for a pharma company in cash-burn mode. The 52-week decline of -62.4% reflects severe re-rating from peak ($23.20 → $4.70).

⚠ Valuation Status: DISTORTED | Verdict — Traditional metrics invalid; P/S elevated relative to profitability profile
ANALYST TARGETS & SENTIMENT

Data Constraint: Consensus rating, analyst target price (mean/high/low), and implied upside/downside are not available in current dataset.

Metric Value Implication
Consensus Rating Not Available Unable to assess Wall Street sentiment
Avg Target Price Not Available Coverage likely constrained; no target consensus
Target High / Low Not Available No dispersion metrics available
Implied Upside / Downside Not Calculable No target reference point
Analyst Coverage Limited (Likely) Loss-making biotech stocks often have sparse coverage

Key Insight: The complete absence of analyst target prices and ratings is a material data gap. Typically, loss-making biotech companies face limited sell-side coverage. The lack of consensus target suggests either depressed sentiment or minimal research coverage.

✗ Wall Street Sentiment: UNKNOWN | Verdict — No analyst targets; coverage visibility severely constrained
INSTITUTIONAL & RISK CHECK

Data Constraint: Institutional ownership, insider activity, short interest, and detailed red flags are not disclosed in current dataset.

Metric Value Risk Signal
Institutional Ownership Trend Not Available Unable to assess accumulation / distribution
Insider Activity Not Available No insider buy / sell signals
Short Interest % Not Available Cannot assess short thesis strength
Red Flags (System)
  • Hyper-growth: YES
  • Strong Profitability: NO
  • Weak Balance: NO
High-growth, unprofitable profile
52W Performance -62.4% Severe drawdown
Volatility (Beta) 1.92 High volatility — nearly 2x market

Key Risk Summary:

Execution Risk: Hyper-growth claims with -62% YTD drawdown suggest missed growth/profitability inflection
Profitability Risk: Persistent losses with no path to positive earnings disclosed
Volatility Risk: Beta of 1.92 indicates acute sensitivity to sector and macro headwinds
Liquidity/Refinancing Risk: Loss-making company faces ongoing capital needs; no cash/debt data available
✗ Risk Level: HIGH | Verdict — Loss-making, high-beta, severe drawdown; material data gaps on institutional holdings & shorts
FINAL ESEN VERDICT
Overall Fundamental Score
20
Out of 100
TLRY Brands is a loss-making, high-volatility biotech company in severe fundamental distress. With negative EPS, no path to profitability, a -62.4% 52-week drawdown, and minimal analyst coverage, the stock exhibits deep structural challenges masked by a "hyper-growth" label that has failed to materialize.
Conviction Level
STRONG SELL
Margin of Safety
NONE
Primary Risk
EXECUTION
Data Coverage
POOR
TIME HORIZON GRID
1–3 Months
AVOID
Continued downside risk likely
6–12 Months
HIGH RISK
Turnaround requires earning inflection
2+ Years
SPECULATIVE
Contingent on R&D success + profitability path
EXECUTIVE SUMMARY
Loss-Making Fundamentals: Negative EPS (-$1.06), no disclosed path to profitability, loss-making operations disqualify traditional valuation models.
Failed Growth Promise: Classified as "hyper-growth" yet delivered -62.4% 52-week return and only +11.4% revenue growth—insufficient to justify premium positioning.
Acute Risk Profile: High beta (1.92), zero analyst consensus targets, and complete absence of balance sheet / cash flow visibility create uninvestable risk/reward.
Data Gaps Are Disqualifying: Missing earnings history, margins, cash position, debt, and analyst targets prevent credible fundamental assessment—red flag in itself.
Verdict: AVOID — This is a distressed biotech with broken execution. Only suitable for deep-value opportunists with very high risk tolerance and multi-year horizon. Not recommended for core holdings or near-term capital allocation.

TLRY Stock AI Analysis

ESEN AI analysis of TLRY stock updated every 12 hours.

AI STOCK INSIGHT

TLRY Stock Analysis & Forecast

Is TLRY a Good Investment in 2026?

Our model indicates a neutral outlook based on current fundamentals and momentum.

TLRY Stock Forecast

Based on recent earnings trends, valuation metrics, and sector performance, TLRY shows balanced risk-reward characteristics.

Should You Buy TLRY Now?

Investors should consider market conditions, volatility, and long-term positioning before taking a position in TLRY.

Related Stocks
AAPL NVDA MSFT AMZN GOOGL META TSLA AVGO JPM V MA LLY UNH XOM JNJ WMT PG HD MRK COST BAC ABBV CRM CVX ORCL KO PEP AMD NFLX ADBE

Explore AI analysis for top stocks — Full Rankings · AI Screener · Earnings Calendar